<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Chen H</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Early screening of clinically significant prostate cancer (csPCa) may offer opportunities in revolutionizing the survival benefits of this lethal disease. We sought to introduce a modified prostate health index density (mPHI) model using imaging indicators and to compare its diagnostic performance for early detection of occult onset csPCa within the prostate-specific antigen (PSA) gray zone with that of PHI and PHID.&lt;h4>Methods and participation&lt;/h4>Between August 2020 and January 2022, a training cohort of 278 patients (total PSA 4.0-10.0 ng/ml) who were scheduled for a prostate biopsy were prospectively recruited. PHI and PHID were compared with mPHI (LDTRD×APD×TPV×PHI) for the diagnosis performance in identifying csPCa. Pathology outcomes from systematic prostate biop</pubmed_abstract><journal>Frontiers in oncology</journal><pagination>864111</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9021722</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.</pubmed_title><pmcid>PMC9021722</pmcid><pubmed_authors>Qian Y</pubmed_authors><pubmed_authors>Shi B</pubmed_authors><pubmed_authors>Gu Z</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Qu F</pubmed_authors><pubmed_authors>Ding J</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.</name><description>&lt;h4>Background&lt;/h4>Early screening of clinically significant prostate cancer (csPCa) may offer opportunities in revolutionizing the survival benefits of this lethal disease. We sought to introduce a modified prostate health index density (mPHI) model using imaging indicators and to compare its diagnostic performance for early detection of occult onset csPCa within the prostate-specific antigen (PSA) gray zone with that of PHI and PHID.&lt;h4>Methods and participation&lt;/h4>Between August 2020 and January 2022, a training cohort of 278 patients (total PSA 4.0-10.0 ng/ml) who were scheduled for a prostate biopsy were prospectively recruited. PHI and PHID were compared with mPHI (LDTRD×APD×TPV×PHI) for the diagnosis performance in identifying csPCa. Pathology outcomes from systematic prostate biop</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-20T00:17:59.476Z</modification><creation>2025-02-19T01:53:47.969Z</creation></dates><accession>S-EPMC9021722</accession><cross_references><pubmed>35463344</pubmed><doi>10.3389/fonc.2022.864111</doi></cross_references></HashMap>